Consolidated Statement of Cash Flows - USD ($) $ in Thousands	2 Months Ended	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2017
Cash flows from operating activities:
Net loss	$ (1,657)	$ (83,440)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	1,434	8,717
Depreciation	0	61
Purchase of in-process research and development expense	0	13,117
Changes in the fair value of the warrant liability	0	27,518
Unrealized currency translation	0	140
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	0	(3,221)
Income tax receivable	0	(105)
Deferred tax assets	0	(208)
Accounts payable	0	3,329
Accrued expenses	223	11,755
Due to Roivant Sciences Ltd. and Roivant Sciences, Inc.	0	4,009
Deferred rent	0	113
Net cash used in operating activities	0	(18,215)
Cash flows from investing activities:
Purchase of furniture and equipment	0	(967)
Net cash used in investing activities	0	(967)
Cash flows from financing activities:
Cash proceeds from issuance of common shares in initial public offering, net of underwriting discount	0	202,275
Initial public offering costs paid	0	(2,311)
Cash capital contribution from Roivant Sciences Ltd.	0	1,035
Due to Roivant Sciences Ltd. and Roivant Sciences, Inc. for amounts paid on behalf of the Company	0	(979)
Net cash provided by financing activities	0	200,020
Net change in cash	0	180,838
Cash—beginning of period	0	0
Cash—end of period	0	180,838
Non-cash investing and financing activities:
Purchase of in-process research and development	0	13,117
Supplemental disclosure of cash paid:
Income taxes	$ 0	$ 240